Trials / Completed
CompletedNCT00575471
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled 12-Week Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivoglitazone HCl | 0.5 mg tablets once daily for 12 weeks |
| DRUG | rivoglitazone HCl | 1.0 mg tablets once daily for 12 weeks |
| DRUG | rivoglitazone HCl | 1.5 mg tablets once daily for 12 weeks |
| DRUG | Placebo | Matching placebo tablets once daily for 12 weeks |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2007-12-18
- Last updated
- 2009-03-02
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00575471. Inclusion in this directory is not an endorsement.